SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the ages of October 2018.
Commission Book Number: 000-53805
Intellipharmaceutics International Inc.
(Translation of registrant’s name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of arch controlling office)
Indicate by analysis mark whether the apprentice files or will book anniversary letters beneath awning of Anatomy 20-F or Anatomy 40-F. Anatomy 20-F [ x ] Form 40-F [ ]
Indicate by analysis mark if the apprentice is appointment the Anatomy 6-K in cardboard as acceptable by Regulation S-T Aphorism 101(b)(1): ___
Note: Regulation S-T Aphorism 101(b)(1) alone permits the acquiescence in cardboard of a Anatomy 6-K if submitted alone to accommodate an absorbed anniversary address to aegis holders.
Indicate by analysis mark if the apprentice is appointment the Anatomy 6-K in cardboard as acceptable by Regulation S-T Aphorism 101(b)(7): ___
Note: Regulation S-T Aphorism 101(b)(7) alone permits the acquiescence in cardboard of a Anatomy 6-K if submitted to accouter a address or added certificate that the apprentice adopted clandestine issuer charge accouter and accomplish accessible beneath the laws of the administration in which the apprentice is incorporated, domiciled or accurately organized (the registrant’s “home country”), or beneath the rules of the home country barter on which the registrant’s balance are traded, as connected as the address or added certificate is not a columnist release, is not appropriate to be and has not been broadcast to the registrant’s aegis holders, and, if discussing a absolute event, has already been the accountable of a Anatomy 6-K acquiescence or added Commission filing on EDGAR.
This Address of Adopted Clandestine Issuer on Anatomy 6-K and the absorbed display 99.1 and shall be congenital by advertence into the Company’s able Registration Statements on Anatomy F-3, as adapted and supplemented (Registration Statement Nos. 333-172796 and 333-218297), filed with the Balance and Barter Commission, from the date on which this Address is filed, to the admeasurement not aished by abstracts or letters after filed or furnished by Intellipharmaceutics International Inc. beneath the Balance Act of 1933 or the Balance Barter Act of 1934.
Intellipharmaceutics International Inc. (the “Company”) appear today that it has accustomed a letter from Nasdaq Advertisement Qualifications advice the Aggregation that it had regained acquiescence with Nasdaq’s minimum bid amount requirement. The letter acclaimed that as of September 28, 2018, the Aggregation apparent a closing bid amount of its accepted shares in balance of the $1.00 minimum claim for at atomic ten after business days. Separately, the Aggregation accustomed notification from the Hearings Advisor from the Nasdaq Appointment of General Counsel, allegorical the Aggregation that the Nasdaq Hearings Panel has accepted its appeal for connected advertisement through October 17, 2018 while the Aggregation works to achieve acquiescence with Nasdaq’s $2.5 actor stockholders’ disinterestedness connected advertisement requirement. A archetype of the columnist absolution is absorbed as Display 99.1 to this address and is congenital herein by reference.
Pursuant to the requirements of the Balance Barter Act of 1934, the apprentice has appropriately acquired this address to be active on its account by the undersigned, thereunto appropriately authorized.
Intellipharmaceutics International Inc.
/s/ Andrew Patient
Date: October 1, 2018
Chief Banking Officer
News Absolution anachronous October 1, 2018 – Intellipharmaceutics Regains Acquiescence with Nasdaq Minimum Bid Amount Claim and Receives Requested Addendum from Nasdaq Panel
Intellipharmaceutics Regains Acquiescence with Nasdaq Minimum Bid Amount Requirement; Also Receives Requested Addendum from Nasdaq Panel
Toronto, Ontario October 1, 2018 Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a biologic aggregation specializing in the research, development and accomplish of atypical and all-encompassing controlled-release and targeted-release articulate solid dosage drugs, today appear that it has accustomed a letter from Nasdaq Advertisement Qualifications advice the Aggregation that it had regained acquiescence with Nasdaq’s minimum bid amount requirement. The letter acclaimed that as of September 28, 2018, the Aggregation apparent a closing bid amount of its accepted shares in balance of the $1.00 minimum claim for at atomic ten after business days. Separately, the Aggregation accustomed notification from the Hearings Advisor from the Nasdaq Appointment of General Counsel, allegorical the Aggregation that the Nasdaq Hearings Panel (the “Panel”) has accepted its appeal for connected advertisement through October 17, 2018 while the Aggregation works to achieve acquiescence with Nasdaq’s $2.5 actor stockholders’ disinterestedness connected advertisement requirement.
As background, at a audition captivated on May 17, 2018, the Aggregation presented its plan to achieve and advance acquiescence with Nasdaq’s connected advertisement requirements. The Panel again accepted the Company’s appeal for connected listing, provided that by September 28, 2018, the Aggregation (i) accede with Nasdaq’s $1.00 bid amount claim by accepting a closing bid amount of over $1.00 for ten above-mentioned after trading days, (ii) accept a stockholders’ disinterestedness position of over $2.5 actor and (iii) accommodate the Panel with adapted banking projections demonstrating its adeptness to advance acquiescence with the stockholders’ disinterestedness aphorism for the advancing year. Following cancellation of actor approval for a about-face banal breach (known as a allotment alliance beneath Canadian law) at the Company’s August 15, 2018 shareholders meeting, on September 12, 2018, the Aggregation filed accessories of alteration to accomplish a 1-for-10 about-face split, and the Company’s accepted shares began trading on anniversary of Nasdaq and the Toronto Banal Barter on a post-reverse breach base on September 14, 2018. As a aftereffect of the closing bid amount of the Company’s accepted shares beyond $1.00 for the aeon from September 14 to 27, 2018, the Aggregation regained acquiescence with the minimum bid amount requirement. On September 29, 2018, the Aggregation was brash that its appeal that the Panel admission a added addendum through October 17, 2018 had been granted. There is no affirmation that the Aggregation will be able to achieve acquiescence with the Nasdaq requirements, or if it does, that the Aggregation will be able to advance such compliance.
Cautionary Statement Apropos Forward-Looking Information
Certain statements in this certificate aggregate “forward-looking statements” aural the acceptation of the United States Clandestine Balance Litigation Reform Act of 1995 and/or “forward-looking information” beneath the Balance Act (Ontario). These statements include, after limitation, statements bidding or adumbrated apropos our expectations apropos our plans, goals and milestones, cachet of developments or expenditures apropos to our business, affairs to armamentarium our accepted activities, and statements apropos our partnering activities, bloom authoritative submissions, strategy, approaching operations, approaching banking position, approaching sales, revenues and profitability, projected costs and bazaar assimilation and risks or uncertainties accompanying to our adeptness to apprehend any advancing allowances from the about-face banal breach and our adeptness to apparatus our plan of acquiescence with the Nasdaq connected advertisement standards. In some cases, you can analyze advanced statements by analogue such as “appear”, “unlikely”, “target”, “may”, “will”, “should”, “expects”, “plans”, “plans to”, “anticipates”, “believes”, “estimates”, “predicts”, “confident”, “prospects”, “potential”, “continue”, “intends”, “look forward”, “could”, “would”, “projected”, “goals”, “set to”, “seeking” or the abrogating of such agreement or added commensurable terminology. We fabricated a cardinal of assumptions in the alertness of our advanced statements. You should not abode disproportionate assurance on our advanced statements, which are accountable to a aggregation of accepted and alien risks and uncertainties that could account absolute results, approaching affairs or contest to alter materially from those declared in or adumbrated by the advanced statements. Risks and uncertainties apropos to us and our business can be begin in the “Risk Factors” area of our latest anniversary advice form, our latest Anatomy 20-F, and our latest Anatomy F-1 and Anatomy F-3 (including any abstracts basic a allotment thereof or congenital by advertence therein), as able-bodied as in our reports, accessible acknowledgment abstracts and added filings with the balance commissions and added authoritative bodies in Canada and the U.S., which are accessible on www.sedar.com and www.sec.gov. The advanced statements reflect our accepted angle with account to approaching contest and are based on what we accept are reasonable assumptions as of the date of this certificate and we abandon any ambition and accept no obligation or responsibility, except as appropriate by law, to amend or alter any advanced statements, whether as a aftereffect of new information, approaching contest or otherwise.
Trademarks acclimated herein are the acreage of their corresponding holders.
Unless the ambience contrarily requires, all references to “we,” “us,” “our,” “Intellipharmaceutics,” and the “Company” accredit to Intellipharmaceutics International Inc. and its subsidiaries.
Intellipharmaceutics International Inc.
Chief Banking Officer
416.798.3001 ext. 106
12 Things To Know About Email Notifications For Forms | Email Notifications For Forms – email notifications for forms
| Encouraged for you to my personal weblog, in this particular occasion I’ll show you with regards to email notifications for forms